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Abstract
Buruli ulcer (BU) is a neglected tropical disease caused by Mycobacterium ulcerans. The tissue damage characteristic of BU
lesions is known to be driven by the secretion of the potent lipidic exotoxin mycolactone. However, the molecular action of
mycolactone on host cell biology mediating cytopathogenesis is not fully understood. Here we applied two-dimensional
electrophoresis (2-DE) to identify the mechanisms of mycolactone’s cellular action in the L929 mouse fibroblast proteome.
This revealed 20 changed spots corresponding to 18 proteins which were clustered mainly into cytoskeleton-related
proteins (Dync1i2, Cfl1, Crmp2, Actg1, Stmn1) and collagen biosynthesis enzymes (Plod1, Plod3, P4ha1). In line with
cytoskeleton conformational disarrangements that are observed by immunofluorescence, we found several regulators and
constituents of both actin- and tubulin-cytoskeleton affected upon exposure to the toxin, providing a novel molecular basis
for the effect of mycolactone. Consistent with these cytoskeleton-related alterations, accumulation of autophagosomes as
well as an increased protein ubiquitination were observed in mycolactone-treated cells. In vivo analyses in a BU mouse
model revealed mycolactone-dependent structural changes in collagen upon infection with M. ulcerans, associated with the
reduction of dermal collagen content, which is in line with our proteomic finding of mycolactone-induced down-regulation
of several collagen biosynthesis enzymes. Our results unveil the mechanisms of mycolactone-induced molecular
cytopathogenesis on exposed host cells, with the toxin compromising cell structure and homeostasis by inducing
cytoskeleton alterations, as well as disrupting tissue structure, by impairing the extracellular matrix biosynthesis.
Citation: Gama JB, Ohlmeier S, Martins TG, Fraga AG, Sampaio-Marques B, et al. (2014) Proteomic Analysis of the Action of the Mycobacterium ulcerans Toxin
Mycolactone: Targeting Host Cells Cytoskeleton and Collagen. PLoS Negl Trop Dis 8(8): e3066. doi:10.1371/journal.pntd.0003066
Editor: Pamela L. C. Small, University of Tennessee, United States of America
Received March 20, 2014; Accepted June 20, 2014; Published August 7, 2014
Copyright:  2014 Gama et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper and its
Supporting Information files.
Funding: The research leading to these results has received funding from the European Community’s Seventh Framework Program (FP7/2007–2013) under grant
agreement Nu 241500 (BuruliVac), from Fundac¸a˜o Calouste Gulbenkian and from Projeto Estrate´gico – LA 26 – 2013–2014 (PEst-C/SAU/LA0026/2013). JBG, TGM
and AGF had a personal grant from the Portuguese Science and Technology Foundation (FCT) (SFRH/BD/33573/2009, SFRH/BD/41598/2007 and SFRH/BPD/
68547/2010, respectively). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* Email: jpedrosa@ecsaude.uminho.pt
" These authors are joint senior authors on this work.
{ Deceased.
Introduction
Buruli ulcer (BU) is a neglected tropical disease caused by
Mycobacterium ulcerans infection [1]. Infection usually starts in the
subcutaneous tissue and initially gives rise to non-ulcerative lesions.
Histologically, increasing areas of necrosis contrast with the smaller
central zone, in which acid-fast bacilli concentrate [2] during both an
intracellular phase as well as extracellularly [3,4]. With disease
progression, necrosis advances, radiating from the focus of infection
and involving all cells and structures in its path [5]. If left untreated,
necrosis extends to the corium and the lesion breaks down into a
severe ulcer. In the ulcerative stage of the disease bacteria disseminate
and become predominantly extracellular [3,4], being found through-
out the necrotic tissue [5]. The treatment of BU consists primarily in a
lingering antibiotic protocol with a combination of rifampicin and
streptomycin [6], however surgical resection of infected skin is still
necessary for advanced stages [7]. Moreover, the frequent delay in
treatment seeking hampers disease management and increases
morbidity [8], with serious long-term sequelae [9]. Prevention is also
difficult as little is known about disease transmission [10,11,12,13,14]
and no vaccine is currently available [15,16].
M. ulcerans pathogenicity and the tissue damage characteristic
of BU are mediated by its toxin mycolactone, a potent cyto-
toxic and immunosuppressive polyketide-derived macrolide
[2,17,18,19,20,21,22]. Mycolactone is produced as a mixture of
congeners, with one major form, which is conserved within a given
geographical area [23]. Mycolactone A/B is the main variant
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produced by African isolates; Australian isolates produce myco-
lactone C [23] and the Chinese isolate MU98912 used in this
study produces mycolactone D [24]. Regarding mycolactone’s
action, in vitro studies mainly performed in the mouse fibroblast
L929 cell line have shown that the toxin diffuses passively through
the plasma membrane [25]. Further studies also show that cells
incubated with the toxin display a distinctive cytopathicity,
characterized by early actin cytoskeleton rearrangement, cell
round-up and detachment from the bottom of the well, and an
arrest in the G0/G1-phase [17,26], culminating in an apoptotic
cell death [19]. Recently, Guenin-Mace´ et al. unveiled that the
toxin targets the actin-cytoskeleton regulator Wiskott-Aldrich
syndrome protein (WASP), inducing its hyperactivation [27],
and Hall et al. described that mycolactone inhibits co-translational
translocation of proteins into the endoplasmic reticulum (ER), thus
inhibiting the production of nearly all proteins that transit through
the ER [28]. However, despite these advances, the molecular
action of this toxin on the host cell biology that drives its
pathogenesis is not fully understood.
This work had the purpose of conducting a characterization of the
proteome of mycolactone-treated cells, in order to better understand
the effects of this toxin on host cell biology. At first, we performed a
kinetic characterization of mycolactone’s cytopathic, cytostatic and
cytotoxic effects on L929 cells. Based on this, specific incubation
times and toxin doses were chosen for the proteomic study by two-
dimensional electrophoresis (2-DE). Functional studies were per-
formed in both in vitro and in vivo models to verify our findings in
mycolactone-exposed cells and investigate their role in BU
pathogenesis. The data obtained showed that cytoskeleton and
collagen biosynthesis are severely affected by mycolactone, support-
ing the involvement of cytoskeleton on mycolactone-induced
cytopathogenicity and identifying a new activity of the toxin on
the decrease of the collagen content in M. ulcerans-infected tissues.
Results
Kinetic characterization of mycolactone cytopathic,
cytostatic and cytotoxic effects
The time- and dose-dependent kinetics of the cytostatic and
cytotoxic activities of mycolactone were investigated by an
integrated analysis of cell cycle and cell death in L929 cells. Doses
of mycolactone were selected through a pre-screening MTS assay
based on the concentrations reported for human ulcer exudates
(0–300 ng/mL) [29]. MTS assay showed a threshold around
15 ng/mL, above which mycolactone is progressively cytotoxic
reaching a plateau at 50 ng/mL (data not shown). Therefore, the
range of mycolactone concentrations tested in this study was
narrowed to 12.5–50 ng/mL.
Results presented in figure 1 show that the ethanol (vehicle)
equivalent (,0.002%), as well as the mycolactone concentration
below the threshold (12.5 ng/mL), had no detectable cytopathic
(rounding and detachment) or cytotoxic effects. Cytotoxic doses of
mycolactone (.12.5 ng/mL) induced detachment, cell cycle arrest
in G0/G1 phase at 48 h and 72 h of treatment and the appearance
of a sub-G0/G1 population, compatible to apoptotic cells, more
evident at 72 h (figure 1A). Consistent with cell cycle data,
annexin-V/PI assays revealed an annexin-V+/PI2 population for
the highest mycolactone concentrations (25 and 50 ng/ml) at 72 h
(figures 1B), indicative of apoptotic cells.
It was previously reported that cells incubated with mycolactone
re-grow when mycolactone is removed from the medium,
indicating that mycolactone’s effect might be reversible [17]. To
further investigate the reversibility of mycolactone’s effect, cells
were incubated with different concentrations of mycolactone for
48 h and afterwards washed and incubated in fresh media for an
extra 48 h period (figure 1, 48 h+48 h). We found that cells that
had previously been incubated with the lowest cytotoxic concen-
tration of the toxin (25 ng/mL) re-adhere, recover the normal cell
cycle progression (figure 1A, 48 h+48 h) and appeared to over-
come the cytotoxic stimulus, since no increase in the sub-G0/G1 or
annexin-V+/PI2 populations was observed (figures 1A and 1B,
48 h+48 h). On the other hand, cells that had been previously
incubated with the highest cytotoxic dose (50 ng/mL), while
remaining in suspension, were not able to overcome the initial
stress induced by mycolactone and became committed to death
(figures 1A and 1B, 48 h+48 h). These data demonstrate that the
reversibility of mycolactone’s effect occurs within a window of
concentrations around 25 ng/mL.
Overall, within the range of studied mycolactone concentra-
tions, we found doses that did not induce observable cytotoxic
effects, doses that induced a reversible stress, and doses that
irreversibly triggered an apoptotic cell death.
To further characterize our model, the kinetics of the cytopathic
effects, namely cytoskeleton alterations and cell round-up and
detachment, were also assessed. In cells incubated with myco-
lactone, we observed not only the previously described alterations
for actin [26], but also changes in the tubulin cytoskeleton, which
appeared bended into a microtubule hank (figure 2A). Within 12–
18 h of exposure to the toxin, actin ultrastructures (stress fibers
and lamellipodia) were lost, and, although still attached, most of
the cells were completely round-up by 18–24 h (figures 2A and
2B). At 24 h, half of the cells were already in suspension, while the
remaining cells eventually detached in the following 12 h [26]:
detachment being probably a consequence of cell round-up and
loss of adhesion structures.
Mycolactone causes time-dependent proteomic changes
related to cytoskeleton and collagen biosynthesis
To study the effects of mycolactone on host cell biology, the
total cellular proteome from mouse fibroblast L929 cells incubated
with 50 ng/mL of mycolactone (dose that triggers a commitment
to apoptotic cell death) or the ethanol equivalent (control), was
separated by 2-DE. To establish a temporal perspective of
mycolactone’s action, three incubation times were chosen: 24 h
(when cells are detaching, but viable and mounting a response
to the mycolactone-induced stress, associating with the first
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detectable consequences of mycolactone on the fibroblast
proteome); 48 h (when cells become committed to death,
coinciding with the onset of an apoptotic population); and 48 h+
48 h, (when most of the cells are in the process of apoptotic cell
death, with only 40% of viability) (figure 1).
The comparison of control cells proteome at different time-
points did not reveal any significantly changed spots, showing that
ethanol (vehicle) represents a suitable control. In contrast, the
comparison between the proteome of control and mycolactone-
treated cells at each time-point revealed a time-dependent increase
in the number of changed spots, with 4 spots changed at 24 h, 10
at 48 h and 20 at 48 h+48 h. All 20 spots were identified by mass
spectrometry and found to correspond to 18 proteins comprising 5
up- and 13 down-regulated (figure 3 and figure 4).
To reveal the cellular processes altered by mycolactone, the
proteins were clustered into functional groups according to
UniProt database (www.uniprot.org). The major groups comprised
(i) cytoskeleton-related proteins (Dync1i2, Cfl1, Crmp2, Actg1,
Stmn1); (ii) stress response proteins (Hspa1b, Uba52); and (iii)
collagen biosynthesis enzymes (Plod1, Plod3, P4ha1) (figure 4 and
figure S1). This reveals that mycolactone results in an alteration of
cytoskeleton-related proteins and down-regulation collagen bio-
synthesis enzymes. On the other hand, stress response proteins
were up-regulated. An additional group (caspase targets) was
created clustering proteins identified as caspase substrates (Fdps,
Psme3, Btf3) through the web caspase substrates database
CASBAH (www.casbah.ie) [30]. Consistent with being caspase
substrates, these proteins were only decreased in the last time point
(48 h+48 h) when most of the cells were undergoing an apoptotic
death process (figure 1). Four additional proteins were classified as
miscellaneous proteins (Prdx4, BSA, Unc119b, Ftl1) (figure 4 and
figure S1).
Overall, the proteome of mycolactone-treated cells revealed that
the intracellular structure (cytoskeleton) and the extracellular
matrix (collagen) are severely affected by the M. ulcerans toxin.
Intracellular structure: Mycolactone impairs cytoskeleton
dynamics and functions
The proteomic study revealed several regulators and structural
components of both microfilaments and microtubules affected by
mycolactone treatment after 24 h (Dync1i2, Cfl1), 48 h (Crmp2,
Actg1) and 48 h+48 h (Stmn1) (figure 4 and figure S1).
Cytoplasmic dynein 1 intermediate chain 2 (Dync1i2) is a non-
catalytic subunit of the microtubule-associated molecular motor
dynein, which is involved in the transport of elements of the Golgi
apparatus, endosomes and lysosomes [31]. The here detected early
(24 h) down-regulation of Dync1i2 (spot 1) suggests that this
transport may be compromised in mycolactone-treated cells.
Three other proteins altered in cells treated with the toxin are
cytoskeleton regulators (Cfl1, Crmp2, Stmn1). Cofilin 1 (Cfl1, spot
4), a well-established regulator of actin dynamics, promotes
microfilament assembly or disassembly depending upon the
concentration of Cfl1 relative to actin and other actin-binding
proteins, as well as upon its phosphorylation status [32]. Collapsin
response mediator protein 2 (Crmp2), which was identified in two
spots (spot 6 and 7), is a multifunctional adaptor protein which can
induce microtubule assembly by binding to ab-tubulin heterodi-
mers [33], whereas stathmin (Stmn1, spot 18) has been described
as a microtubule-destabilizing oncoprotein [34]. Interestingly, the
isoelectric points (pIs) of spots 4 (Cfl1) and 6 (Crmp2) differed in
the gel from their expected theoretical values (figure 3 and
figure 4), suggesting posttranslational modification such as phos-
phorylation. Given that the regulatory activity of Cfl1 [32] and
Crmp2 [33] can be modulated by phosphorylation, we studied the
phospho-status of these proteins with the Pro Q Diamond
phosphostaining. Indeed, the analysis of the phosphoprotein
stained gel revealed that both spots were phosphorylated (figure
S2). Thus, mycolactone increases the phospho-Cfl1 at 24 h,
decreases both phosphorylated and non-phosphorylated forms of
Crmp2 at 48 h, and decreases Stmn1 in the latest time point
(48 h+48 h).
Figure 1. Kinetics of mycolactone cytostatic and cytotoxic effects. Mouse fibroblasts L929 cells were incubated for 24, 48 or 72 hours either
with ethanol or indicated concentrations of mycolactone. Additionally, an assay was performed where cells were incubated for 48 hours in the same
conditions followed by a 48 hour incubation period in fresh medium (referred to as 48 h+48 h). Cell cycle analysis (A) and annexin-V/PI assay (B) were
performed for each-time point. Bars represent the mean + SD (n = 3) from one out of, at least, two independent experiments. Each condition was
compared to EtOH-treated samples throughout each time-point (24 h, 48 h and 72 h) by Two-way ANOVA with Bonferroni posttest; statistical
differences were represented by *** (P,0.001) for sub-G0/G1 and Annexin-V
+/PI2 , and by ### (P,0.001) for G0/G1 Phase and Annexin-V
+/PI+. Each
condition at 48 h+48 h time-point was compared with the same condition at the 48 h by Two-way ANOVA with Bonferroni posttest; statistical
differences were represented by &&& (P,0.001) for sub-G0/G1 and Annexin-V
+/PI2, and by 111 (P,0.001) for G0/G1 Phase and Annexin-V
+/PI+.
doi:10.1371/journal.pntd.0003066.g001
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In addition to the alteration of cytoskeleton regulators, the
proteomic study revealed that the cytoskeleton is also altered on its
structural components. Actin gamma (Actg1), a component of
microfilaments, is down-regulated at 48 h in mycolactone-treated
cells.
Overall, these results show that cells exposed to mycolactone
undergo a process of cytoskeleton remodeling involving regulators
and structural components, providing a novel molecular basis for
the effect of mycolactone on this organelle.
Mycolactone impairs autophagy, a cytoskeleton-
dependent cellular function
Two stress response proteins (Hspa1b, Uba52) were up-
regulated upon treatment with mycolactone. Spot 10 (figure 4
and figure S1) was identified as a fusion protein (Uba52) consisting
of N-terminal ubiquitin and C-terminal 60S ribosomal protein
L40. The detected spot position in the gel (figure 3) in comparison
with the theoretical positions for the fusion protein (pI 9.87/
14.7 kDa), ubiquitin (pI 6.56/8.6 kDa) and the ribosomal protein
(pI 10.32/6.2 kDa) suggest the presence of ubiquitin. Indeed, all
three spot-specific peptides covered amino acids 13–55 revealing
that ubiquitin is present. The here detected increase of free
ubiquitin after 48 h of mycolactone treatment could result from an
inhibition of ubiquitin ligases or from an up-regulation of its
expression. To investigate this in more detail, protein ubiquitina-
tion was studied by western blot, which revealed that mycolactone
exposure results in an increase of ubiquitinated proteins, more
evident at 48 h and 48 h+48 h (figure 5A). Therefore, these data
show that rather than an inhibition of ubiquitin ligases,
mycolactone induces an up-regulation of the ubiquitin/protea-
some system (UPS).
The UPS and the lysosomal degradation system (autophagy) are
the two main cellular degradative pathways. These systems
crosstalk each other and the up-regulation of one may occur in
response to a down-regulation/dysfunction of the other. Autoph-
agy is known to be dependent on microtubule cytoskeleton [35]
and dynein-driven transport [36] with dynein playing a role in the
delivery of autophagosome contents to lysosomes during autopha-
gosome-lysosome fusion [36]. Since microtubules (Figure 2) and
dynein (figure 4 and figure S1) were found to be affected by
mycolactone, we hypothesized that the mycolactone-induced
cytoskeleton-related changes might impair the autophagic process
leading to the up-regulation of the UPS. Therefore the role of
mycolactone in autophagy was further investigated.
During autophagy the cytosolic form of LC3 (LC3-I) is
conjugated to phosphatidylethanolamine (PE) to form LC3-PE
(LC3-II), which is recruited to autophagosomal membranes. As
the autophagosomes fuse with lysosomes to form autolysosomes,
LC3-II is degraded together with the intra-autophagosomal
components by lysosomal hydrolases. Thus, lysosomal turnover
of the autophagosomal marker LC3-II reflects autophagic activity
[37]. Processing of this marker was analyzed by western blot and
immunofluorescence. Western blot revealed an increase of the
autophagosome marker LC3-II in cells treated with mycolactone
(figure 5B) compatible with an inhibition of autolysomes forma-
tion. In agreement, an increase of LC3-positive cytoplasmic
vesicles upon toxin exposure was also detected with the
immunofluorescence assay (figure 5C, red-stained). To further
understand these results, we treated L929 cells with different
stimuli and added bafilomycin A1 to inhibit the autolysosomal
degradation step [38] 2 hours before protein extraction (fig-
ure 5D). The increase of LC3-II induced by mycolactone
(figure 5B and 5C), together with the lack of difference in LC3-
II in cells treated with mycolactone in the presence or absence of
bafilomycin A1 (figure 5C), suggests a block of autophagy at the
terminal stages [39]. Furthermore, the higher LC3-I levels
observed in cells exposed to mycolactone, when compared with
cells where autophagy was induced by rapamycin (figure 5C),
suggests that most probably autophagy is being induced due to cell
detachment [40] or as a feedback response to the blockage of the
autophagic terminal stage. These data indicate that mycolactone
inhibits autophagosome-lysosome fusion and in turn impairs
autophagy.
Taken together, this reveals that mycolactone mediates up-
regulation of the UPS and inhibition of autophagy. Since
autophagy counteracts several stresses, including infection by
intracellular pathogens [41,42,43], mycolactone-induced impair-
ment of autophagy may have implications for the progress of M.
ulcerans infection.
Extracellular matrix: Mycolactone impairs collagen
biosynthesis
Proteomics identified several enzymes of collagen biosynthesis
progressively down-regulated in mycolactone-treated cells: Plod1
(24 h), Plod3 (48 h) and two isoforms of P4ha1 (48 h+48 h).
Further studies showed that these proteins were transcriptionally
down-regulated after 24 h of mycolactone exposure (figure S3),
thus the differential down-regulation of the different proteins
probably reflects different protein stability. These enzymes
catalyze the hydroxylation of lysine (Plod1 and Plod3) and proline
(P4ha1) residues, which is essential for the formation and
stabilization of collagen fibers [44,45]. The here detected down-
regulation of these enzymes suggests that collagen fibers stability
may be compromised in mycolactone exposed cells. Interestingly,
histopathological studies from the 1960’s reported a collagen
decrease in human BU lesions [5,46,47]; however this feature has
been overlooked and it was never subject to studies to determine
its cause or its relevance for BU.
To investigate if mycolactone was responsible for a decrease in
tissue collagen, an experimental model of BU disease, the mouse
footpad infection with M. ulcerans, was used. Mice were
challenged with virulent mycolactone-secreting (MU98912), avir-
ulent mycolactone-negative (MU5114) strains of M. ulcerans or
PBS as a control. Pathology progression was assessed by measuring
footpad swelling (figure 6A) and, at different time-points, footpads
were collected for histological processing and collagen scoring
(figure 6B). The results showed that, in footpads infected with
mycolactone-secreting M. ulcerans (MU98912), the progressive
increase of pathology (figure 6A) was associated with a decrease of
the collagen score (figure 6B), preceding the breakdown of the
lesion into an ulcer (by day 40 post-infection). In contrast, infection
with the mycolactone-negative strain (MU5114) did not induce
pathology nor did it alter the collagen content in infected footpads,
similar to what was observed for the PBS-injected control group
Figure 2. Mycolactone induces cytoskeletal alteration, cell round up and detachment. Mouse fibroblasts L929 cells seeded on coverslips
were incubated for 12, 18 or 24 hours either with ethanol or 50 ng/mL of mycolactone. Cytoskeletal changes were visualized by immunofluorescence
microscopy using rhodamine-phalloidin conjugate (red) and a tubulin-specific antibody (green). Nuclei were stained with 49,6-diamidino-2-
phenylindole (DAPI). The cellular shape was visualized by differential interference contrast (DIC) microscopy. White horizontal bar represents a 10 mm
scale (A). Blue (nucleus) and red (actin) channels were used for 3D remodeling of the respective confocal z stacks (B).
doi:10.1371/journal.pntd.0003066.g002
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(figure 6A and 6B). These results suggest that the decrease in
collagen content is not a consequence of the infection or the
elicited immune response, but rather caused by mycolactone. To
verify this, mice were challenged with purified toxin or ethanol
equivalent as control. The results showed that mycolactone
induced footpad swelling associated with a decrease of the collagen
score, while the vehicle did not (figure 6D and 6E). Histological
samples stained with Masson’s trichrome showed a decay of
collagen fibers in MU98912-infected or mycolactone-treated
footpads, characterized by the disorganization and thinness of
collagen fibers (figure 6C and 6F).
These results in the mouse model of infection show that the
earlier described degeneration of collagen in BU lesions
[5,46,47,48] is a consequence of the secretion of mycolactone by
the infecting strain.
Discussion
Even though, the methodology used has some limitations, since
it excludes the analysis of transmembrane and secretory proteins,
which were found to be severely affected by mycolactone [28], this
work is the first proteomic study on the effect of mycolactone on
cells, unveiling important information about the toxin action.
It has been known for years that the actin-cytoskeleton of
mycolactone-treated cells suffers early structural rearrangements
[26]. Recently, it was also shown that these changes were mediated
by the mycolactone-induced hyperactivation of the actin-cytoskel-
eton regulator WASP [27]. In this study we show that mycolactone
causes structural changes in microtubules and we identify several
regulators and structural components of both microfilaments and
microtubules affected by the M. ulcerans toxin. These data
confirm the cytoskeleton as a major target of mycolactone and
further specifies the mechanisms of the toxin’s cellular action.
Moreover, given the cytoskeleton’s dynamic nature, with constant
remodeling, it remained unclear how these changes contribute to
the tissue damage characteristic of BU lesions. Since the proteomic
data pointed likewise to an involvement of the UPS further
experiments were performed confirming its mycolactone-depen-
dent up-regulation. UPS and autophagy constitute the main
intracellular processes of protein degradation taking part in the
Figure 3. Mycolactone causes time-dependent proteomic changes. Mouse fibroblasts L929 cells were incubated for 24 or 48 hours either
with ethanol or mycolactone (50 ng/mL). Additionally, an assay was performed where cells were incubated for 48 hours in the same conditions
followed by a 48 hour incubation period in fresh medium (referred to as 48 h+48 h). Representative silver-stained 2-D gels of total protein extracts
(100 mg) are shown for the different exposure times (all analyzed gels are in Supplementary Information). Spots altered upon treatment are
represented by numbers (1–20).
doi:10.1371/journal.pntd.0003066.g003
Figure 4. Altered proteins upon mycolactone treatment. Figure shows the proteins identified for each spot (numbers according to figure 3
and figure S1) clustered into five categories. (1) Expression levels show decreased (red), increased (green) or no changes (black) in spot intensities
upon mycolactone treatment. (2) MS and MS/MS parameters are presented, including the number of specific matched peptides (P), the sequence
coverage (SC) in percentage, as well as the MS scores. Phosphoproteins (*) and putative protein fragments (#) are indicated. Full MS and MS/MS data
in Supplementary Information.
doi:10.1371/journal.pntd.0003066.g004
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cellular protein quality control system. Thus, UPS and autophagy
are critical in the maintenance of cellular homeostasis and their
activities are strictly orchestrated. Moreover, perturbations in the
flux through either pathway have been reported to affect the
activity of the other system, and a number of mechanisms have
been proposed to rationalize the link between the UPS and
autophagy [49]. Therefore, it was investigated if the detected
mycolactone-dependent changes affect autophagy. The here
Figure 5. Mycolactone causes an up-regulation of the ubiquitin-proteasome pathway and an accumulation of autophagosomes. In
A, B and C, mouse fibroblasts L929 cells were incubated for 24 or 48 hours either with ethanol (2) or mycolactone (50 ng/mL, +). Additionally, an
assay was performed where cells were incubated for 48 hours in the same conditions followed by a 48 hour incubation period in fresh medium
(referred to as 48 h+48 h). At each time-point, total protein was extracted and Western blot was performed to assess ubiquitinated proteins (A) or
LC3 processing (B). Additionally, cytospins were made to assess immunofluorescence LC3 (red). White horizontal bars represent a 10 mm scale (C). In
D, mouse fibroblasts L929 cells were incubated for 48 hours either with ethanol or mycolactone (50 ng/mL) and bafilomycin A1 (10 nM, +) or DMSO
(vehicle control, 2) was added 2 hours prior the end of the assay. Additionally, mouse fibroblast L929 cells were incubated for 48 hours without any
stimuli until 2 hours prior the end of the assay, when autophagy was induced with rapamycin (1 mM), and bafilomycin A1 (10 nM, +) or DMSO
(vehicle control, 2) was added. At the end of the assay, total protein was extracted and Western blot was performed to assess LC3 processing (D).
doi:10.1371/journal.pntd.0003066.g005
Mycolactone Action on Host Cells: Proteomic and Functional Study
PLOS Neglected Tropical Diseases | www.plosntds.org 8 August 2014 | Volume 8 | Issue 8 | e3066
Figure 6. Mycolactone induces a decrease in dermal collagen fibers.Mice were infected with virulent mycolactone-secreting (MU98912: dark
gray triangles) (n = 5) or avirulent mycolactone-negative (MU5114: light gray squares) (n = 4) strains of M. ulcerans, or injected with PBS (vehicle: white
circles) (n = 3) as a control (A, B and C). Alternatively, mice were inoculated with 5 mg of mycolactone (dark gray hexagons) (n = 4) or ethanol (vehicle:
white diamonds) (n = 4) as a control (D, E, F). Lesion progression was assessed by measurement of footpad swelling (A and D). Collagen content was
assessed by a qualitative blind scoring of the amount of dermal collagen fibers (score 0 = lowest, 4 = highest) visualized in HE-stained sections by
polarized light (B and E). The different groups were compared to the control groups (PBS in A and B; ethanol in C and D) by Two-way ANOVA with
Bonferroni posttest; statistical differences were represented by ** (P,0.01) or *** (P,0.001). Additionally, mouse footpads exposed to the different
stimuli were stained with Masson’s trichrome to highlight collagen fibers (green) (C and F). On panel are depicted representative histological image
each group. Black horizontal bars represent a 50 mm scale. Histological structures like dermis (D) and the stratum corneum (SC) and stratum spinosum
(SS) of the epidermis (ED) are indicated on the upper-left image. Inflammatory infiltrate is indicated by an asterisk.
doi:10.1371/journal.pntd.0003066.g006
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obtained data indicate that autophagosome-lysosome fusion is
impaired in mycolactone-treated cells. Given that the delivery of
autophagosome contents to lysosomes is dependent on microtu-
bule cytoskeleton [35] and on dynein-driven transport [36], the
mycolactone-induced impairment of autophagy appears to occur
secondarily to mycolactone-induced cytoskeleton alterations.
Further evidence of a dysfunctional vesicle-lysosome fusion is
given by another altered protein in mycolactone-treated cells.
Proteomics revealed that the cell culture medium constituent BSA
(clustered on miscellaneous proteins) was increased in cells treated
with mycolactone. As degradation of extracellular proteins occurs
in lysosomes [50], the observed BSA accumulation suggests
likewise that the endosomes-lysosome fusion may be compro-
mised. Since the delivery of autophagosome to lysosomes [36] and
retrograde transport of endosomes [31] is mediated by dynein the
here observed down-regulation of one of its components
(Dync1i2), suggest an impairment of dynein-driven transport
upon mycolactone exposure. Further work is needed to explore the
effect of mycolactone on cytoskeletal motors-mediated transport,
however the down-regulation of a molecular motor subunit
(Dync1i2) together with the microfilaments’ and microtubules’
architectural changes, induced by the toxin, hint at a dysfunctional
cytoskeletal motors-mediated transport within mycolactone-treat-
ed cells. Other cytoskeleton dependent functions, like phagocytosis
[51,52], cell motility [27] and cell shape [17] are also described to
be impaired in mycolactone treated cells. Thus, these evidences
imply that mycolactone induces a nonfunctional cytoskeletal-
architecture, affecting cytoskeleton-dependent functions, with
consequences for cellular homeostasis. Moreover, our proteomic
study revealed several regulators and structural constituents of
both actin- and tubulin-cytoskeleton (Cfl1, Crmp2, Stmn1 and
Actg1) affected by mycolactone. These alterations may reflect a
cell feedback response to the abnormal cytoskeletal architecture
as an attempt to restore the physiological cytoskeletal conforma-
tion and dynamics. In particular, the early alterations found on
cofilin, a well-known regulator of actin dynamics [32], and on
dynein, recently found to play a role in the production of normal
bundled stress fibers [53], may represent an immediate cellular
response to actin polymerization mediated by mycolactone-
induced WASP hyperactivation [27]. Thus, a growing body of
evidences supports a model in which the cytoskeletal disarrange-
ment induced by mycolactone impairs multiple cytoskeleton-
dependent cellular functions with cytotoxic consequences for the
host cells.
These cytoskeletal changes might have also implications early
on infection, during the M. ulcerans intracellular phase, when the
pathogen has to survive and proliferate inside the host cell [3,4].
Autophagy is being increasingly recognized as an important
component of immunity, playing specific roles in shaping the
immune system development, fuelling host innate and adaptive
immune responses, and directly controlling intracellular microbes
as a cell-autonomous innate defense mechanism. As an evolution-
ary counterpoint, intracellular pathogens have evolved to block
autophagic microbicidal defenses and subvert host autophagic
responses for their survival or growth [41,42]. Importantly, studies
have implicated autophagy in the control of many pathogenic
bacteria [43], from which M. tuberculosis [54] should be
highlighted here due to its genetic proximity to M. ulcerans.
Thus, the mycolactone-induced impairment of autophagy, medi-
ated by its action over the cytoskeleton, might represent a
virulence mechanism of M. ulcerans to impair host cell immunity
against intracellular pathogens.
One of the main findings of this work is the identification of a
novel activity of mycolactone, with the demonstration of its role in
the decrease of collagen content in M. ulcerans-infected tissues.
Collagen decrease in human BU lesions was described in the
1960’s, in the first histopathological studies of this disease
[5,46,47], however, this phenomenon has been overlooked, even
when, more recently, Guarner et al. described this feature as one
of the most reliable criteria for the histopathological diagnosis of
BU [48]. This previously unappreciated feature of the disease was
never subject to studies to determine its cause or its relevance for
BU progression and associated sequelae.
Here we link, for the first time, the activity of mycolactone
with the collagen reduction in M. ulcerans-infected tissues. Our
results from the in vivo model show that collagen decrease is not
a consequence of the infection or the immune response, but of
the presence of mycolactone. In fact the inoculation of the
purified toxin shows an association between decrease of collagen
and the presence of mycolactone. In vitro, we showed that in
L929 cells mycolactone transcriptionally down-regulated several
ER-resident collagen-modifying enzymes (Plod1, Plod3 and two
isoforms of P4ha1). Additionally, Hall et al. described a post-
transcriptional mechanism in which mycolactone blocks co-
translational translocation of proteins into the ER, thus
inhibiting the synthesis of the majority of ER-resident (like the
collagen-modifying enzymes) and secretory proteins (like extra-
cellular matrix proteins) [28]. Although these mechanisms have
not been verified in vivo, altogether, these data suggest that
mycolactone inflicts a transcriptional and post-transcriptional
inhibition of the collagen biosynthesis pathway, which translate
into a degeneration of collagen fibers in mycolactone-exposed
tissues.
Our data also show that the mycolactone-induced collagen
degeneration precedes the breakdown of the lesion into an ulcer,
suggesting that collagen decrease may be involved, together with
cell death, in the tissue destructuration that culminates in the
emergence of an M. ulcerans-induced ulcerative lesion. Moreover,
it may be a mechanism of pathogen dissemination, given that in
early lesions bacteria concentrate in a smaller central zone, while
in advanced lesions bacilli are dispersed throughout the necrotic
area. Finally, this collagen decay in BU lesions may also be
implicated in the development of the sequelae characteristic of this
devastating skin disease. BU has a very high morbidity rate
associated with contractures [9]. Wound contraction is a natural
mechanism by which open wounds close during the healing
process, but also results in significant tissue distortion with loss of
joint mobility and cosmetic disfigurement. Although the mecha-
nism of wound contraction is not fully understood, it is associated
with the abnormal generation of thicker collagen fibers [55,56,57].
Therefore, it is conceivable that during the healing process,
fibroblasts and myofibroblasts repopulating the lesion overcome
the collagen-deficiency through abnormal- or over-production
of collagen leading to the extreme contractures characteristic of
BU [58]. In fact, a recent paper by Andreoli et al. described an
increase in activated myofibroblasts and an abundant produc-
tion of extracellular matrix proteins in antibiotic-treated BU
lesions [59]. Further studies are needed to test this hypothesis,
but if proven correct the use of collagen-based materials as a
bed for the skin graft, or even as a replacement in smaller
legions, may decrease the contracture and thus the morbidity in
BU patients.
Overall, our results provide molecular and functional evidence
of the impact of mycolactone on the cytoskeleton and cytoskel-
eton-dependent cellular functions, and extend our knowledge on
the action of the M. ulcerans toxin to collagen biosynthesis,
providing new perspectives on BU pathogenesis and paving the
way for future therapeutic approaches.
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Materials and Methods
Bacteria
M. ulcerans strains were selected from the Institute of Tropical
Medicine collection in Antwerp, Belgium. MU5114 is a myco-
lactone-negative strain due to repeated subculturing, leading to the
spontaneous loss of genes involved in mycolactone synthesis
[23,60]. MU98912 is highly virulent for mice [22] and produces
mycolactone type D [24]. The isolates were grown on Mid-
dlebrook 7H9 medium (Becton, Dickinson and Company) with
1.5% of agar at 32uC for approximately 6–8 weeks. For the
preparation of the inoculum, M. ulcerans was recovered, vortexed
using glass beads and diluted in phosphate-buffered saline pH 7.4
(PBS) to a final concentration of 1 mg/ml.
Mycolactone extraction/purification
Protocol for mycolactone extraction/purification was adapted
from the one previously described [17]. Briefly, MU98912 was
cultured in Dubos medium supplemented with 10% oleic acid-
albumin-dextrose complex, at 32uC. At late exponential growth
phase, bacteria were harvested and lipids were extracted with
chloroform and methanol (2:1) for 4 hours. The organic phase was
separated from bacterial debris and hydrophilic components by
addition of a 0.2 volume of water, followed by centrifugation. The
organic phase was dried and resuspended in ice-cold acetone. The
individual lipid components of the acetone-soluble lipid fraction
were separated by chromatography using the CycloGraph system
(Analtech). The separated fractions were analyzed by thin layer
chromatography, and the fractions corresponding to mycolactone
were pooled, dried down, weighed, resuspended in absolute
ethanol, and stored at 280uC under nitrogen atmosphere in the
dark [61]. Purified mycolactone was analyzed by mass spectrom-
etry (MS detector Thermo LxQ linear ion trap) and the presence
of mycolactone D confirmed. Under these conditions, mycolac-
tone was stable for at least three years.
In vitro experimental design
Mouse fibroblasts L929 cell line was cultured in Dulbecco’s
Modified Eagle Medium (DMEM) (Gibco) supplemented with
10% fetal bovine serum (Gibco), 2 mM L-glutamine (Gibco),
10 mM HEPES (Gibco), 1 mM sodium pyruvate (Gibco) and
antibiotic-antimycotic (Gibco). Cells were expanded in 175 cm2
flasks (Nunc) until 90% confluence. Then, cells were plated in 12-
wells plates (Nunc) at a density of 2.56105 cells/well, with
increasing concentrations of mycolactone or with ethanol equiv-
alent (,0.002%), as a control. Rapamycin (Calbiochen) and
Bafilomycin A1 (Sigma) was used to induce autophagy and to
block autolysosome degradation, respectively.
Cell cycle analysis
At each time-point, cells were collected and a pool of adherent
and suspended cells was made. Cells were rinsed and resuspended
in PBS. Absolute ethanol was gently added until 70% final
concentration. Cells were stored in this fixing solution at 4uC.
When all time-points had been collected, cells were rinsed in PBS
and incubated with staining solution (0.1% triton-X-100, 20 mg/
mL of propidium iodide, 250 mg/mL of RNase in PBS) for one
hour in a bath at 50uC, in the dark. Samples were analyzed by
flow cytometry (LSRII, BD).
Annexin-V/PI assay
The protocol was done according to the manufacturer’s instruc-
tions (BD Pharmingen). At each time-point cells were collected and a
pool of adherent and suspended cells was made. Cells were rinsed,
stained and analyzed by flow cytometry (LSRII, BD).
Cytoskeleton imaging
L929 cells were allowed to adhere to coverslips (Nunc) overnight
following the incubation in different conditions. Cells were rinsed
and fixed in paraformaldehyde, for 1 hour, at room temperature.
Cells were rinsed and stored in PBS at 4uC. When all time-points had
been collected, cells were blocked with blocking solution (5% BSA,
0.1% triton-X-100, 0.1% tween-20 in PBS) and incubated overnight
at 4uC with the mouse anti-tubulin antibody (AA4.3, developed by
C. Walsh and obtained from the Developmental Studies Hybridoma
Bank, developed under the auspices of the National Institute of Child
Health and Human Development and maintained by The University
of Iowa, Department of Biology). Cells were rinsed and incubated
with secondary AF488 goat anti-mouse antibody (Invitrogen) and
rhodamine-phalloidin conjugate (Invitrogen) for 1 hour, at room
temperature, in the dark. Cells were visualized using a confocal
microscope (FV1000, Olympus) with660 objective. 3D remodeling
was performed using Fluoview software (Olympus).
Protein extraction
At each time-point, cells were collected and a pool of adherent and
suspended cells was made. Cells were rinsed with PBS, resuspended in
Lysis Buffer (50 mM Tris-HCl pH7.2, 250 mM NaCl, 2 mM EDTA,
1% NP-40, 10% Glycerol, protease inhibitor (Roche #11873580001)
and phosphatase inhibitor (Roche #04906837001)) and stored at
280uC, until protein was extracted at the end of the experiment.
When all time-points had been collected, samples were thawed,
incubated for 30 minutes at 4uC with agitation, sonicated in a
ultrasonic ice cold bath for 1 minute until no agglomerate was seen
and centrifuged (30 minutes, 14000 rpm, 4uC). The supernatant
was considered the total protein extract. For Western Blot analysis,
protein concentration was determined (Thermo Scientific #23227)
and aliquots stored at 280uC.
Two-dimensional gel electrophoresis (2-DE)
Protein was precipitated in 80% (v/v) acetone and the protein
pellet resuspended in urea buffer (7 M urea, 2 M thiourea, 4% (w/v)
CHAPS, 0.15% (w/v) DTT, 0.5% [v/v] carrier ampholytes and
Complete Mini protease inhibitor cocktail). The protein separation
was done as previously described [62]. Briefly, 100 mg protein
extract was diluted with urea buffer to a final volume of 420 mL and
in-gel rehydration was performed overnight. IEF was carried out in
IPG strips (pH 3–10, non-linear, 18 cm; GE Healthcare, Uppsala,
Sweden) with the Multiphor II system (GE Healthcare) under
paraffin oil for 55 kVh. SDS-PAGE was done overnight in
polyacrylamide gels (12.5% T, 2.6% C) with the Ettan DALT II
system (GE Healthcare) at 1–2 W per gel and 12uC. The gels were
silver stained and analyzed with the 2-DE image analysis software
Melanie 3.0 (Gene-Bio, Geneva, Switzerland). To verify the
reproducibility three biological replicates for each time point and
condition as well as three technical replicates were analyzed (all
analyzed gels are in Supplementary Information). An expression
change was considered significant if the intensity of the correspond-
ing single spot differed reproducibly more than twofold and was
reproducible for all three experiments. The expected spot position in
the 2D-gel according to the known protein sequence was calculated
with the Compute pI/Mw tool (http://ca.expasy.org/tools/pi_tool.
html). For the detection of phosphorylated proteins 400 mg of protein
were separated by 2-DE, stained with Pro-Q Diamond Phospho-
protein Gel Stain (Molecular Probes), according to the manufactur-
er’s instructions, scanned to detect the phosphorylation signals, silver
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stained and rescanned. Images of both scans were matched with the
2-DE image analysis software Melanie 3.0 (Gene-Bio).
Mass spectrometry (MS)
For the protein identification, 400 mg of protein were separated
by 2-DE. Selected spots were excised, digested with trypsin
(recombinant; Roche), and prepared as described earlier [62]. In
brief, the extracted and dried peptides were dissolved in 5 ml
alpha-Cyano-3-hydroxycinnamic acid (98%, recrystallized from
ethanol-water, 5 mg/ml in 50% acetonitrile and 0.1% TFA) and
0.5 ml applied onto the sample plate using the dried-droplet
method. Peptide masses were measured with a UltrafleXtreme
MALDI-TOF/TOF (Bruker, Billerica, MA, USA). Proteins were
identified according to their spot-specific peptide mass fingerprint
and/or peptide sequence with the bioinformatic tool BioTools
Version 3.2 (Bruker) with the following search parameters
(tolerance: MS = 10–50 ppm, MS/MS = 0.5–0.9 Da, enzyme:
Trypsin, engine: Mascot, database: NCBInr, modifications:
Oxidation (M)). A protein identification was accepted if at least
three major peaks matched to the protein with the highest score
(full MS and MS/MS data in Supplementary Information).
If the protein spot was detected at a lower molecular mass than
expected, suggesting processing or fragmentation, the spot-specific
peptides in the mass spectrum were also analyzed to confirm which parts
of the corresponding protein sequence matched with these peptides. If
the mass spectrum of the spot lacked peptides observed for the complete
protein and had a different position in the 2D gel than expected it was
indicated as a protein fragment. Therefore, both the spot position
observed by 2-DE and the specific peptides in the corresponding mass
spectrum were analyzed to indicate a putative protein fragment.
Western blot analysis
40 mg of protein were resolved in a 12% SDS-PAGE and
transferred to the 0.2 mm Nitrocellulose membranes (Bio-Rad
#170-4159) with the semi-dry Trans-Blot Turbo system (Bio-Rad).
Membranes were blocked and subjected to immunoblotting with
GAPDH antibody (CellSignaling #2118), LC3A/B antibody
(CellSignaling#4108) or mono- and polyubiquitinylated conjugates
antibody (Enzo Life Sciences #PW8810), followed by incubation
with horseradish peroxidase linked secondary antibodies (Southern
Biotech). Bands were detected with SuperSignal (Thermo Scientific
#34095) in a Universal Hood II (Bio-Rad) and quantified with
QuantityOne (Bio-Rad). GAPDH was used as loading control.
LC3 Immunofluorescence
At each time-point, cells were collected and a pool of adherent
and suspended cells was made. Cytospins were made (Cytospin III,
Shandon) and cells were fixed in paraformaldehyde for 20 minutes
at room temperature and stored in ethanol 96% at 4uC. When all
time-points had been collected, cells were blocked with blocking
solution (5% BSA, 0.1% triton-X-100, 0.1% tween-20 in PBS) and
incubated overnight at 4uC with the LC3A/B antibody (Cell-
Signaling #4108). Normal Rabbit IgG Control (R&D Systems
AB-105-C) was used as isotype control. Cells were rinsed and
incubated with secondary AF568 goat anti-rabbit antibody
(Invitrogen) for 1 hour, at room temperature, in the dark. Cells
were visualized using a confocal microscope (FV1000, Olympus)
with 660 objective.
In vivo experimental design
Eight-weeks-old female BALB/c mice were obtained from
Charles River (Barcelona, Spain) and housed under
specific-pathogen-free conditions with food and water ad libitum.
Mice were infected in the left hind footpad with 30 mL of M.
ulcerans suspensions with 4.8 log10 AFBs, or 30 mL PBS as control.
Footpad thickness was evaluated every 2–3 days. Mice were
sacrificed weekly and footpads were harvested for histological
studies.
Ethics statement
The in vivo studies were approved by the Portuguese national
authority for animal experimentation Direc¸a˜o Geral de Veterina´ria
(ID: DGV 594 from 1st June 2010). Animals were kept and
handled in accordance with the guidelines for the care and
handling of laboratory animals in the Directive 2010/63/EU of
the European Parliament and of the Council.
Collagen assessment
Footpads were harvested, fixed in 10% phosphate-buffered
formalin and embedded in paraffin. Tissue sections were stained
with hematoxylin and eosin (H&E), analyzed by light microscopy
with polarized light and the amount of dermal collagen fibers was
blindly scored from 0 (lowest) to 4 (highest) independently by two
persons in two independent experiments. Additionally, tissue
sections were stained with Masson’s trichrome and pictures were
taken in a light microscopy.
RT-qPCR
At each time-point, cells were collected and a pool of adherent
and suspended cells was made. Cells were rinsed, resuspended in
TRIzol Reagent (Ambion) and stored at 280uC, until total RNA
was extracted, at the end of the experiment, according to the
manufacturer’s protocol.
Reverse transcription was done with whole RNA using
RevertAid H Minus First Strand cDNA Synthesis Kit (Fermentas)
according to the manufacturer’s instructions. qPCR was
perform on the C1000TM Thermo Cycler (Bio-Rad) using
TaqMan Gene Expression Assay (AB Applied Biosystems)
(Plod1: Mm01255769_m1; Plod3: Mm00478798_m1; P4ha1:
Mm00803137_m1; B2m: Mm00437762_m1; Gapdh:
Mm99999915_g1; Hprt: Mm00446968_m1). Relative quantifica-
tion was determined with CFX Manager Software (Bio-Rad) using
B2m, Gapdh and Hprt as reference genes.
Statistical analysis
Differences between the means of experimental groups were
analyzed using the Prism version 5.0 software (GraphPad).
Percentage and fraction values were transformed to and analyzed
as arcsin values. Differences were considered significant only with
a P value,0.001, in the in vitro studies; or with a P value,0.01,
in the in vivo study.
Supporting Information
Figure S1 Mycolactone treatment affects mainly cyto-
skeleton related proteins and collagen biosynthesis
enzymes. Enlarged parts of silver-stained 2-D gel of total protein
extracts (100 mg) of L929 cells treated either with ethanol or
mycolactone (50 ng/mL), showing the identified altered spots
clustered into five categories. Arrows and circles represent
conditions where the spot intensity is increased or decreased,
respectively. Phosphoproteins are indicated by an asterisk (*) and
putative protein fragments are indicated by a number sign (#). For
P4ha1 the number of the specific isoform is indicted in
parentheses.
(TIF)
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Figure S2 Spots 4 and 6 are phosphoproteins. Enlarged
parts of silver- and phospho-stained 2-D gel showing the spot 4
(Cfl1) and the spot 6 (Crmp2) in both stainings.
(TIF)
Figure S3 Mycolactone treatment induces a transcrip-
tional down-regulation of collagen biosynthesis en-
zymes. Mouse fibroblasts L929 cells were incubated for 24 or
48 hours either with ethanol (white) or mycolactone (50 ng/mL,
gray). Additionally, an assay was performed where cells were
incubated for 48 hours in the same conditions followed by a
48 hour incubation period in fresh medium (referred to as 48 h+
48 h). At each time-point, total RNA was extracted and Plod1,
Plod3, P4ha1 mRNA levels assessed. Bars represent the mean +
SD from two independent experiments with three technical
replicas (n = 6). Mycolactone-treated was compared to EtOH-
treated samples throughout each time-point (24 h and 48 h) by
Two-way ANOVA with Bonferroni posttest; statistical differences
were represented by *** (P,0.001). Each condition at 48 h+48 h
time-point was compared with the same condition at the 48 h by
Two-way ANOVA with Bonferroni posttest; statistical differences
were represented by &&& (P,0.001).
(TIF)
Dataset S1 2D gels from L929 cells incubated for
24 hours with ethanol.
(ZIP)
Dataset S2 2D gels from L929 cells incubated for
48 hours with ethanol.
(ZIP)
Dataset S3 2D gels from L929 cells incubated for
48 hours with ethanol followed by a 48 hour incubation
period in fresh medium (referred to as 48 h+48 h).
(ZIP)
Dataset S4 2D gels from L929 cells incubated for
24 hours with mycolactone.
(ZIP)
Dataset S5 2D gels from L929 cells incubated for
48 hours with mycolactone.
(ZIP)
Dataset S6 2D gels from L929 cells incubated for
48 hours with mycolactone followed by a 48 hour
incubation period in fresh medium (referred to as
48 h+48 h).
(ZIP)
Dataset S7 MS and MS/MS data.
(ZIP)
Acknowledgments
The authors would like to thank Goreti Pinto for microscopy assistance.
This article is dedicated to the memory of Prof. Manuel T. Silva, deceased
on 10 April 2012.
Author Contributions
Conceived and designed the experiments: JBG SO JP PL. Performed the
experiments: JBG SO TGM AGF BSM. Analyzed the data: JBG SO MTS
JP PL. Contributed reagents/materials/analysis tools: SO MAC FP JP PL.
Contributed to the writing of the manuscript: JBG SO AGF BSM JP PL.
References
1. MacCallum P, Tolhurst JC, Sı`ssons HA (1948) A new mycobacterial infection in
man. J Pathol Bacteriol 60: 93–122.
2. Connor DH, Lunn HF (1965) Mycobacterium ulcerans infection (with
comments on pathogenesis). Int J Lepr 33: Suppl:698–709.
3. Silva MT, Portaels F, Pedrosa J (2009) Pathogenetic mechanisms of the
intracellular parasite Mycobacterium ulcerans leading to Buruli ulcer. Lancet
Infect Dis 9: 699–710.
4. Torrado E, Fraga AG, Castro AG, Stragier P, Meyers WM, et al. (2007)
Evidence for an intramacrophage growth phase of Mycobacterium ulcerans.
Infect Immun 75: 977–987.
5. Connor DH, Lunn HF (1966) Buruli Ulceration: A clinicopathologic study of 38
Ugandans with Mycobacterium ulcerans ulceration. Arch Pathol 81: 183–199.
6. World Health Organization (2004) Provisional guidance on the role of specific
antibiotics in the management of Mycobacterium ulcerans disease (Buruli ulcer).
WHO/CDS/CPE/GBUI/2004 10: 33.
7. Kibadi K, Boelaert M, Fraga AG, Kayinua M, Longatto-Filho A, et al. (2010)
Response to treatment in a prospective cohort of patients with large ulcerated
lesions suspected to be Buruli Ulcer (Mycobacterium ulcerans disease). PLoS
Negl Trop Dis 4: e736.
8. Quek TY, Henry MJ, Pasco JA, O’Brien DP, Johnson PD, et al. (2007)
Mycobacterium ulcerans infection: factors influencing diagnostic delay.
Med J Aust 187: 561–563.
9. Ellen DE, Stienstra Y, Teelken MA, Dijkstra PU, van der Graaf WT, et al.
(2003) Assessment of functional limitations caused by Mycobacterium ulcerans
infection: towards a Buruli ulcer functional limitation score. Trop Med Int
Health 8: 90–96.
10. Marsollier L, Robert R, Aubry J, Saint Andre JP, Kouakou H, et al. (2002)
Aquatic insects as a vector for Mycobacterium ulcerans. Appl Environ Microbiol
68: 4623–4628.
11. Marsollier L, Severin T, Aubry J, Merritt RW, Saint Andre JP, et al. (2004)
Aquatic snails, passive hosts of Mycobacterium ulcerans. Appl Environ
Microbiol 70: 6296–6298.
12. Marsollier L, Brodin P, Jackson M, Kordulakova J, Tafelmeyer P, et al. (2007)
Impact of Mycobacterium ulcerans biofilm on transmissibility to ecological
niches and Buruli ulcer pathogenesis. PLoS Pathog 3: e62.
13. Portaels F, Meyers WM, Ablordey A, Castro AG, Chemlal K, et al. (2008) First
cultivation and characterization of Mycobacterium ulcerans from the environ-
ment. PLoS Negl Trop Dis 2: e178.
14. Merritt RW, Walker ED, Small PL, Wallace JR, Johnson PD, et al. (2010)
Ecology and transmission of Buruli ulcer disease: a systematic review. PLoS Negl
Trop Dis 4: e911.
15. Nackers F, Dramaix M, Johnson RC, Zinsou C, Robert A, et al. (2006) BCG
vaccine effectiveness against Buruli ulcer: a case-control study in Benin.
Am J Trop Med Hyg 75: 768–774.
16. Fraga AG, Martins TG, Torrado E, Huygen K, Portaels F, et al. (2012) Cellular
immunity confers transient protection in experimental Buruli ulcer following
BCG or mycolactone-negative Mycobacterium ulcerans vaccination. PLoS One
7: e33406.
17. George KM, Chatterjee D, Gunawardana G, Welty D, Hayman J, et al. (1999)
Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for
virulence. Science 283: 854–857.
18. Pahlevan AA, Wright DJ, Andrews C, George KM, Small PL, et al. (1999) The
inhibitory action of Mycobacterium ulcerans soluble factor on monocyte/T cell
cytokine production and NF-kappa B function. J Immunol 163: 3928–3935.
19. George KM, Pascopella L, Welty DM, Small PL (2000) A Mycobacterium
ulcerans toxin, mycolactone, causes apoptosis in guinea pig ulcers and tissue
culture cells. Infect Immun 68: 877–883.
20. Torrado E, Adusumilli S, Fraga AG, Small PL, Castro AG, et al. (2007)
Mycolactone-mediated inhibition of tumor necrosis factor production by
macrophages infected with Mycobacterium ulcerans has implications for the
control of infection. Infect Immun 75: 3979–3988.
21. Torrado E, Fraga AG, Logarinho E, Martins TG, Carmona JA, et al. (2010)
IFN-gamma-dependent activation of macrophages during experimental infec-
tions by Mycobacterium ulcerans is impaired by the toxin mycolactone.
J Immunol 184: 947–955.
22. Oliveira MS, Fraga AG, Torrado E, Castro AG, Pereira JP, et al. (2005)
Infection with Mycobacterium ulcerans induces persistent inflammatory
responses in mice. Infect Immun 73: 6299–6310.
23. Mve-Obiang A, Lee RE, Portaels F, Small PL (2003) Heterogeneity of
mycolactones produced by clinical isolates of Mycobacterium ulcerans:
implications for virulence. Infect Immun 71: 774–783.
24. Hong H, Spencer JB, Porter JL, Leadlay PF, Stinear T (2005) A novel
mycolactone from a clinical isolate of Mycobacterium ulcerans provides
evidence for additional toxin heterogeneity as a result of specific changes in
the modular polyketide synthase. Chembiochem 6: 643–648.
25. Snyder DS, Small PL (2003) Uptake and cellular actions of mycolactone, a
virulence determinant for Mycobacterium ulcerans. Microb Pathog 34: 91–101.
26. George KM, Barker LP, Welty DM, Small PL (1998) Partial purification and
characterization of biological effects of a lipid toxin produced by Mycobacterium
ulcerans. Infect Immun 66: 587–593.
27. Guenin-Mace L, Veyron-Churlet R, Thoulouze MI, Romet-Lemonne G, Hong
H, et al. (2013) Mycolactone activation of Wiskott-Aldrich syndrome proteins
Mycolactone Action on Host Cells: Proteomic and Functional Study
PLOS Neglected Tropical Diseases | www.plosntds.org 13 August 2014 | Volume 8 | Issue 8 | e3066
underpins Buruli ulcer formation. J Clin Invest 123: 1501–12. doi: 10.1172/
JCI66576.
28. Hall BS, Hill K, McKenna M, Ogbechi J, High S, et al. (2014) The pathogenic
mechanism of the Mycobacterium ulcerans virulence factor, mycolactone,
depends on blockade of protein translocation into the ER. PLoS Pathog 10:
e1004061.
29. Sarfo FS, Le Chevalier F, Aka N, Phillips RO, Amoako Y, et al. (2011)
Mycolactone diffuses into the peripheral blood of Buruli ulcer patients–
implications for diagnosis and disease monitoring. PLoS Negl Trop Dis 5: e1237.
30. Luthi AU, Martin SJ (2007) The CASBAH: a searchable database of caspase
substrates. Cell Death Differ 14: 641–650.
31. Allan VJ (2011) Cytoplasmic dynein. Biochem Soc Trans 39: 1169–1178.
32. Bernstein BW, Bamburg JR (2010) ADF/cofilin: a functional node in cell
biology. Trends Cell Biol 20: 187–195.
33. Schmidt EF, Strittmatter SM (2007) The CRMP family of proteins and their role
in Sema3A signaling. Adv Exp Med Biol 600: 1–11.
34. Belletti B, Baldassarre G (2011) Stathmin: a protein with many tasks. New
biomarker and potential target in cancer. Expert Opin Ther Targets 15: 1249–
1266.
35. Webb JL, Ravikumar B, Rubinsztein DC (2004) Microtubule disruption inhibits
autophagosome-lysosome fusion: implications for studying the roles of aggre-
somes in polyglutamine diseases. Int J Biochem Cell Biol 36: 2541–2550.
36. Ravikumar B, Acevedo-Arozena A, Imarisio S, Berger Z, Vacher C, et al. (2005)
Dynein mutations impair autophagic clearance of aggregate-prone proteins. Nat
Genet 37: 771–776.
37. Tanida I, Ueno T, Kominami E (2008) LC3 and Autophagy. Methods Mol Biol
445: 77–88.
38. Klionsky DJ, Elazar Z, Seglen PO, Rubinsztein DC (2008) Does bafilomycin A1
block the fusion of autophagosomes with lysosomes? Autophagy 4: 849–850.
39. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, et
al. (2012) Guidelines for the use and interpretation of assays for monitoring
autophagy. Autophagy 8: 445–544.
40. Fung C, Lock R, Gao S, Salas E, Debnath J (2008) Induction of autophagy
during extracellular matrix detachment promotes cell survival. Mol Biol Cell 19:
797–806.
41. Deretic V, Levine B (2009) Autophagy, immunity, and microbial adaptations.
Cell Host Microbe 5: 527–549.
42. Sumpter R, Jr., Levine B (2010) Autophagy and innate immunity: triggering,
targeting and tuning. Semin Cell Dev Biol 21: 699–711.
43. Gong L, Devenish RJ, Prescott M (2012) Autophagy as a macrophage response
to bacterial infection. IUBMB Life 64: 740–747.
44. Krane SM (2008) The importance of proline residues in the structure, stability
and susceptibility to proteolytic degradation of collagens. Amino Acids 35: 703–
710.
45. Yamauchi M, Sricholpech M (2012) Lysine post-translational modifications of
collagen. Essays Biochem 52: 113–133.
46. Clancey JK, Dodge OG, Lunn HF, Oduori ML (1961) Mycobacterial skin ulcers
in Uganda. Lancet 2: 951–954.
47. Dodge OG (1964) Mycobacterial Skin Ulcers in Uganda: Histopathological and
Experimental Aspects. J Pathol Bacteriol 88: 169–174.
48. Guarner J, Bartlett J, Whitney EA, Raghunathan PL, Stienstra Y, et al. (2003)
Histopathologic features of Mycobacterium ulcerans infection. Emerg Infect Dis
9: 651–656.
49. Korolchuk VI, Menzies FM, Rubinsztein DC (2009) A novel link between
autophagy and the ubiquitin-proteasome system. Autophagy 5: 862–863.
50. Buktenica S, Olenick SJ, Salgia R, Frankfater A (1987) Degradation and
regurgitation of extracellular proteins by cultured mouse peritoneal macrophag-
es and baby hamster kidney fibroblasts. Kinetic evidence that the transfer of
proteins to lysosomes is not irreversible. J Biol Chem 262: 9469–9476.
51. Adusumilli S, Mve-Obiang A, Sparer T, Meyers W, Hayman J, et al. (2005)
Mycobacterium ulcerans toxic macrolide, mycolactone modulates the host
immune response and cellular location of M. ulcerans in vitro and in vivo. Cell
Microbiol 7: 1295–1304.
52. Coutanceau E, Marsollier L, Brosch R, Perret E, Goossens P, et al. (2005)
Modulation of the host immune response by a transient intracellular stage of
Mycobacterium ulcerans: the contribution of endogenous mycolactone toxin.
Cell Microbiol 7: 1187–1196.
53. Meiri D, Marshall CB, Greeve MA, Kim B, Balan M, et al. (2012) Mechanistic
insight into the microtubule and actin cytoskeleton coupling through dynein-
dependent RhoGEF inhibition. Mol Cell 45: 642–655.
54. Songane M, Kleinnijenhuis J, Netea MG, van Crevel R (2012) The role of
autophagy in host defence against Mycobacterium tuberculosis infection.
Tuberculosis (Edinb) 92: 388–396.
55. Ehrlich HP (1988) Wound closure: evidence of cooperation between fibroblasts
and collagen matrix. Eye (Lond) 2 (Pt 2): 149–157.
56. Berry DP, Harding KG, Stanton MR, Jasani B, Ehrlich HP (1998) Human
wound contraction: collagen organization, fibroblasts, and myofibroblasts. Plast
Reconstr Surg 102: 124–131; discussion 132–124.
57. Ehrlich HP, Hunt TK (2012) Collagen Organization Critical Role in Wound
Contraction Advances in Wound Care 1: 3–9.
58. World Health Organization (2006) Buruli ulcer. Prevention of disability (POD).
WHO/CDS/NTD/GBUI/200612.
59. Andreoli A, Ruf MT, Sopoh GE, Schmid P, Pluschke G (2014) Immunohis-
tochemical monitoring of wound healing in antibiotic treated Buruli ulcer
patients. PLoS Negl Trop Dis 8: e2809.
60. Stinear TP, Hong H, Frigui W, Pryor MJ, Brosch R, et al. (2005) Common
evolutionary origin for the unstable virulence plasmid pMUM found in
geographically diverse strains of Mycobacterium ulcerans. J Bacteriol 187:
1668–1676.
61. Marion E, Prado S, Cano C, Babonneau J, Ghamrawi S, et al. (2013)
Photodegradation of the Mycobacterium ulcerans toxin, mycolactones: consid-
erations for handling and storage. PLoS One 7: e33600.
62. Ohlmeier S, Mazur W, Salmenkivi K, Myllarniemi M, Bergmann U, et al.
(2010) Proteomic studies on receptor for advanced glycation end product
variants in idiopathic pulmonary fibrosis and chronic obstructive pulmonary
disease. Proteomics Clin Appl 4: 97–105.
Mycolactone Action on Host Cells: Proteomic and Functional Study
PLOS Neglected Tropical Diseases | www.plosntds.org 14 August 2014 | Volume 8 | Issue 8 | e3066
